688108.SH
赛诺医疗
SSE · Healthcare · Medical - Devices · CN
CNY 17.63
−4.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 564.3M | 525.4M | 458.7M | 343.3M | 192.9M |
| Cost of Revenue | 178.5M | 177.0M | 174.6M | 141.0M | 71.1M |
| Gross Profit | 385.8M | 348.4M | 284.2M | 202.2M | 121.7M |
| Operating Expenses | |||||
| R&D Expense | 121.0M | 122.6M | 140.6M | 114.1M | 152.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 91.1M | 90.7M | 89.5M | 94.6M | 119.5M |
| Selling & Marketing Expense | 80.5M | 77.5M | 79.0M | 63.2M | 55.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 303.6M | 301.2M | 316.3M | 276.4M | 327.6M |
| Cost and Expenses | 482.1M | 478.2M | 490.8M | 417.5M | 398.7M |
| Operating Income (EBIT) | 92.8M | 66.8M | (17.0M) | (69.4M) | (219.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 94.5M | 68.4M | (17.2M) | (67.9M) | (221.3M) |
| Income Tax Expense | 22.7M | 21.0M | (13.3M) | (24.5M) | (48.0M) |
| Bottom Line | |||||
| Net Income | 68.8M | 47.3M | 1.5M | (39.6M) | (162.4M) |
| Earnings from Cont. Ops | 71.8M | 47.5M | (3.9M) | (40.6M) | (173.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 68.8M | 47.3M | 1.5M | (39.6M) | (162.4M) |
| Per Share | |||||
| Basic EPS | CN¥0.16 | CN¥0.11 | CN¥0.00 | (CN¥0.10) | (CN¥0.40) |
| Diluted EPS | CN¥0.16 | CN¥0.11 | CN¥0.00 | (CN¥0.10) | (CN¥0.40) |
| Revenue Per Share | CN¥1.38 | CN¥1.22 | CN¥1.23 | CN¥0.87 | CN¥0.48 |
| Shares | |||||
| Basic Shares Outstanding | 407.7M | 429.9M | 374.4M | 396.3M | 406.0M |
| Diluted Shares Outstanding | 407.7M | 429.9M | 374.4M | 396.3M | 406.0M |
| Profitability Metrics | |||||
| EBITDA | — | 150.0M | 73.4M | 6.0M | (144.7M) |
| D&A | — | 83.2M | 90.3M | 75.5M | 74.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026